Royalty Pharma First Quarter 2025 Earnings: EPS: US$0.41 (vs US$0.011 in 1Q 2024)

Simply Wall St

May 10, 2025

Royalty Pharma (NASDAQ:RPRX) First Quarter 2025 Results

Key Financial Results

Revenue: US$568.0m (flat on 1Q 2024).
Net income: US$238.0m (up by US$233.2m from 1Q 2024).
Profit margin: 42% (up from 0.8% in 1Q 2024).
EPS: US$0.41 (up from US$0.011 in 1Q 2024).

Our free stock report includes 3 warning signs investors should be aware of before investing in Royalty Pharma. Read for free now.

earnings-and-revenue-growth — NasdaqGS:RPRX Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Royalty Pharma Earnings Insights

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Royalty Pharma you should be aware of.

If you're looking to trade Royalty Pharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.